Karyopharm Therapeutics Q4 2023 GAAP EPS $(0.36) Misses $(0.30) Estimate, Sales $33.75M Miss $35.40M Estimate
Karyopharm Therapeutics Q4 2023 GAAP EPS $(0.36) Misses $(0.30) Estimate, Sales $33.75M Miss $35.40M Estimate
Karyopharm Therapeutics 2023年第四季度GAAP每股收益（0.36）未达到预期（0.30）美元，销售额为3,375万美元，低于3540万美元的预期
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.30) by 20 percent. The company reported quarterly sales of $33.75 million which missed the analyst consensus estimate of $35.40 million by 4.68 percent. This is a 0.50 percent increase over sales of $33.58 million the same period last year.
Karyopharm Therapeutics（纳斯达克股票代码：KPTI）公布的季度亏损为每股0.36美元，比分析师普遍预期的0.30美元（0.30美元）低20％。该公司公布的季度销售额为3,375万美元，比分析师普遍预期的3540万美元低4.68％。这比去年同期的3,358万美元的销售额增长了0.50％。